Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01218919
Other study ID # NM-10-017-ID-DB
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date October 2013
Est. completion date December 2013

Study information

Verified date February 2019
Source Abbott Medical Devices
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this study is to evaluate the effectiveness of a rechargeable Deep Brain Stimulation as an adjunctive treatment for reducing some of the symptoms of advanced, levodopa-responsive Parkinson's disease that are not adequately controlled with medication.

This is the first observational study for the use of the BRIO™ rechargeable constant current device, using a lead with an active electrode tip for deep brain stimulation in Parkinson subjects. The current study was designed to conform to normal medical practices, taking into consideration the current day economic constraints, while assessing the best set of circumstances for the successful sustained reduction of some of the symptoms of advanced, levodopa-responsive Parkinson's disease that are not adequately controlled with medication.


Description:

This study is designed as a prospective, observational, non-randomized, multi-centered study for a total of 10 years in duration. It is a 10 year study from system implantation and activation with a yearly database lock and report, with the subjects being used as their own control. The primary outcome assessment will occur at three months. Following completion of the primary outcome assessment, patients will have an annual visit up to 10 years post implant.

Comparison of measures within the same person from pre-treatment to post-treatment will be performed.

During the implantation procedure, each subject will undergo a trial of stimulation in the operating room among other potential assessments to determine proper lead placement. The device may be internalized after a successful intra-operative trial or at a later date according to investigator site practice. The date that all components are implanted and programmed will be classified as "Day 0". After system activation the subject will return to clinic for post-operative evaluations at 1 month (+/-14 days), 3 months (+/-14 days), 6 months (+/-14 days) and 12 months (+/-30 days). Thereafter, a long term data collection program will be followed for 10 years post-implant.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Subject has signed an informed consent.

2. Subject has been diagnosed, by a neurologist, with idiopathic Parkinson's disease.

3. Subject is a candidate for surgery.

4. Subject is 18 to 80 years of age.

5. Subject has a history of improvement of Parkinson's symptoms as a direct result of administering L-dopa to the subject with at least a 25% improvement in UPDRS motor score or subject has been diagnosed with tremor-dominant Parkinson's disease.

6. Subject should be stable on anti-Parkinson's disease medication for at least one month prior to study enrollment

Exclusion Criteria:

1. Subject has any major illness or medical condition that in the opinion of the physician would interfere with participation in the study.

2. Subject has non-treated clinically significant depression or any other significant psychiatric co-morbidities.

3. Subject has any condition requiring repeated MRI scans;

4. Subject is on anticoagulant medications and is unable to interrupt for time of procedure.

5. Subject has dementia that interferes with their ability to co-operate or comply with study requirements or comprehend the Informed Consent as determined by the investigator.

6. Subject abuses drugs or alcohol.

7. Subject has a history of seizure (Neurosurgeon must approve)

8. Subject has confirmation of diagnosis of a terminal illness associated with survival <12 months.

9. Female that is lactating or of childbearing potential with positive urine pregnancy test or not using adequate birth control.

10. Subject has participated in a drug, device or biological trial within the preceding 30 days.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Abbott Medical Devices

Outcome

Type Measure Description Time frame Safety issue
Primary UPDRS motor scores Comparison of Parkinson's symptoms as demonstrated by the UPDRS motor scores in the medication 'Off' state at Baseline compared to the medication 'Off' with stimulation "On" 3 months after device implantation 3 months after device implantation
Secondary PDQ-8 Quality of Life measurements through 3, 6 and 12 months as measured by the PDQ-8 compared to baseline 3, 6 and 12 months compared to baseline
Secondary modified Schwab and England Activities of Daily Living measurement through 3, 6 and 12 months as determined from the modified Schwab and England, compared to baseline 3, 6 and 12 months compared to baseline
Secondary Levodopa dose Comparison of Levodopa dose taken by the subject at baseline and 3, 6 and 12 month after device implantation baseline and 3, 6 and 12 month after device implantation
Secondary Satisfaction of therapy Rate of subject and caregivers therapy satisfaction through 3, 6 and 12 months 3, 6 and 12 months
Secondary IPG Recharging information Evaluation of the subjects/caregivers IPG Recharging information 3 and 12 months
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A